Ontology highlight
ABSTRACT:
SUBMITTER: Khella HWZ
PROVIDER: S-EPMC4817948 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature
Khella Heba W Z HWZ Butz Henriett H Ding Qiang Q Rotondo Fabio F Evans Kenneth R KR Kupchak Peter P Dharsee Moyez M Latif Ashraf A Pasic Maria D MD Lianidou Evi E Bjarnason Georg A GA Yousef George M GM
Molecular therapy : the journal of the American Society of Gene Therapy 20150723 11
Sunitinib is a multitargeting tyrosine kinase inhibitor used for metastatic renal cancer. There are no biomarkers that can predict sunitinib response. Such markers are needed to avoid administration of costly medication with side effects to patients who would not benefit from it. We compared global miRNA expression between patients with a short (≤12 months) versus prolonged (>12 months) progression-free survival (PFS) under sunitinib as first-line therapy for metastatic renal cell carcinoma. We ...[more]